Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An AAV-based bioluminescent reporter reveals dynamic YAP/TAZ-TEAD transcriptional activity during liver injury.

Biochimica et biophysica acta. Molecular basis of disease·2026

Same author

Development and Validation of a Nomogram to Predict Liver Metastases in Patients With Gastric Cancer.

Indian journal of surgical oncology·2026

Same author

Peripheral nervous system involvement in Parkinson's disease: Peripheral neuropathy, neuromuscular junction dysfunction, and clinical implications.

Neuroscience and biobehavioral reviews·2026

Same author

One-Shot Pd(II)-Catalyzed Multiple C-H Activation Enables Modular Construction of Fluorenylidene Oxindole-Based Multi(Polycyclic) Aromatic Enes.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026

Same author

Development of flow cytometry bead-based opsonophagocytic assays to dissect cell-mediated functional antibody responses to malaria vaccines.

Malaria journal·2026

Same author

Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.

European journal of immunology·2026

Same journal

The food additive microbial transglutaminase is a potential new environmental inducer of autoimmune diseases.

Current opinion in immunology·2026

Same journal

Mapping the synovial immune ecosystem in rheumatoid arthritis: cellular cartography and pathotype-guided immune restoration.

Current opinion in immunology·2026

Same journal

Noncanonical ion channel signaling in neurovascular barrier regulation and immune cell trafficking.

Current opinion in immunology·2026

Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026

Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026

Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Local complement inhibition by selective precision-targeted therapies.

Haiyu Wang¹, Daan J van den Brink¹, Balthasar A Heesters²

¹Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.

Current Opinion in Immunology

|October 30, 2025

Summary

This summary is machine-generated.

Targeted complement inhibitors offer a promising new strategy for treating diseases caused by excessive complement activation. Local inhibition reduces risks and costs compared to systemic approaches.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Experiment Videos

Last Updated: Jan 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Area of Science:

Immunology
Pharmacology

Background:

Excessive complement activation is a key factor in numerous serious human diseases.
Current complement inhibitors are typically administered systemically, leading to high costs and increased infection risks.

Purpose of the Study:

To review novel strategies for local complement inhibition.
To focus on tissue-specific targeting using antibody technologies for complement inhibition.

Main Methods:

Review of preclinical and clinical development approaches for local complement inhibition.
Focus on antibody-based tissue-specific targeting strategies.

Main Results:

Local complement inhibition offers potential for lower dosing, reduced costs, and improved safety profiles.
Tissue-specific targeting via antibody technologies is a key area of development.

Conclusions:

Targeted complement inhibitors hold significant promise for selective inhibition at disease sites.
Upcoming therapies aim to mitigate risks associated with systemic complement inhibition.